Accurate accounting of caplacizumab cost effectiveness

Lancet Haematol. 2021 May;8(5):e315. doi: 10.1016/S2352-3026(21)00052-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Purpura, Thrombotic Thrombocytopenic*
  • Single-Domain Antibodies*

Substances

  • Single-Domain Antibodies
  • caplacizumab